AbbVie & Genentech v. Dr. Reddy’s: Venetoclax ANDA Ends in Consent Injunction
AbbVie and Genentech filed suit in Delaware against Dr. Reddy’s Laboratories after it submitted ANDA 214733 seeking approval to market generic venetoclax tablets (10 mg, 50 mg, 100 mg). After 1,610 days of litigation, the parties resolved the dispute via a stipulated consent order that acknowledged ANDA infringement and permanently enjoined Dr. Reddy’s from commercialising its generic product for the life of four asserted patents.
Venetoclax ANDA Battle Ends With Permanent Injunction Against Dr. Reddy’s
Filed on 21 July 2020 in the District of Delaware before Judge Mitchell S. Goldberg, this Hatch-Waxman infringement action was brought by AbbVie, Inc. and Genentech, Inc. — co-owners of the VENCLEXTA® (venetoclax) franchise — against Dr. Reddy’s Laboratories, Ltd. and Dr. Reddy’s Laboratories, Inc. The plaintiffs alleged that the filing of ANDA 214733, seeking FDA approval for generic venetoclax tablets in 10 mg, 50 mg, and 100 mg strengths, constituted a technical act of infringement under 35 U.S.C. § 271(e)(2)(A) with respect to four patents: US10993942B2, US11110087B2, US11369599B2, and US11128599B2.
The case concluded on 17 December 2024 through a stipulated consent order signed by both sides. The court adjudged that the ANDA filing was a technical act of infringement of all four asserted patents. Dr. Reddy’s, its agents, and affiliates were permanently enjoined from manufacturing, selling, offering for sale, or importing the generic venetoclax products described in ANDA 214733 for the full patent term, including any extensions and paediatric exclusivities, absent a licence from the plaintiffs. All remaining claims, counterclaims, and defences were dismissed without prejudice, and both parties expressly waived their right to appeal.
A resolution after more than four years of litigation — spanning complex pharmaceutical patent claim construction and Hatch-Waxman procedure — suggests the parties reached a negotiated outcome rather than proceeding to a full merits trial. The dismissal without prejudice of remaining claims, combined with the carve-out preserving future litigation rights over products other than ANDA 214733, is consistent with a structured settlement. The specific commercial terms of any underlying licence arrangement, if one exists, are not disclosed in the public record.
Filing to Dismissed without Prejudice in 1610 days
1,610 days — over 4.4 years in litigation, well above the median Hatch-Waxman district court timeline
Consent order and injunction: what the stipulated resolution means for both parties
Stipulated consent order — agreed infringement finding and permanent injunction
Under 35 U.S.C. § 271(e)(2)(A), filing an ANDA referencing a patented drug is itself a technical act of infringement, even without commercial sales. The parties agreed by stipulation that ANDA 214733 triggered this provision for all four patents. The consent order is a court-enforceable decree — Dr. Reddy’s cannot commercialise the generic product without breaching the injunction, regardless of future FDA approval status.
Hatch-Waxman § 271(e)(2)(A)AbbVie and Genentech secure full-term exclusivity for VENCLEXTA®
The consent order gives AbbVie and Genentech enforceable protection through the life of all four patents, including any patent-term extensions and paediatric exclusivities. The without-prejudice dismissal of other claims preserves their ability to pursue future actions against Dr. Reddy’s if it files a new ANDA or pursues a different product. The waiver of appeal by Dr. Reddy’s removes the risk of an immediate challenge to the infringement finding.
Full patent-term protection retainedDr. Reddy’s enjoined from launching generic venetoclax under ANDA 214733
Dr. Reddy’s agreed to the infringement finding and accepted a permanent injunction, effectively blocking commercialisation of its 10 mg, 50 mg, and 100 mg generic venetoclax tablets for the duration of the asserted patents. It also waived its right to appeal. The without-prejudice structure, however, leaves open the possibility of pursuing future Paragraph IV challenges on different grounds or with respect to other venetoclax products not covered by ANDA 214733.
Generic launch blocked for patent lifeVENCLEXTA® exclusivity reinforced — BCL-2 inhibitor market remains protected
Venetoclax is a first-in-class BCL-2 inhibitor approved for multiple haematologic malignancies and carries significant commercial value. This consent order, combined with the breadth of the four-patent portfolio covering different aspects of the compound and its formulations, suggests robust exclusivity runway. Other ANDA filers in the venetoclax space should treat this outcome as a strong signal of plaintiffs’ willingness to litigate aggressively and of the portfolio’s enforceability.
BCL-2 inhibitor exclusivity securedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | AbbVie, Inc. | Company | Pharmaceutical innovators — co-holders of venetoclax (VENCLEXTA®) patent portfolioSearch in Eureka ↗ |
| Co-Plaintiff | Genentech, Inc. | Company | Search in Eureka ↗ |
| Defendant | Dr. Reddy’s Laboratories, Ltd. | Company | Generic pharmaceutical manufacturer that filed ANDA 214733 for venetoclax tabletsSearch in Eureka ↗ |
| Co-Defendant | Dr. Reddy’s Laboratories, Inc. | Company | Search in Eureka ↗ |
| Plaintiff counsel | Andrea P. Brockway | Attorney | Counsel for AbbVie, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Ashley N. Mays-Williams | Attorney | Counsel for AbbVie, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Aubrey James Morin | Attorney | Counsel for AbbVie, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Bruce M. Wexler | Attorney | Counsel for AbbVie, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Chad J. Peterman | Attorney | Counsel for AbbVie, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Charles E. Davis | Attorney | Counsel for AbbVie, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Christopher R. Hall | Attorney | Counsel for AbbVie, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Eric W. Dittmann | Attorney | Counsel for AbbVie, Inc.Search in Eureka ↗ |
| Plaintiff counsel | James Darlington Taylor , Jr. | Attorney | Counsel for AbbVie, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Jessica Marie Jones | Attorney | Counsel for AbbVie, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Katherine A. Daniel | Attorney | Counsel for AbbVie, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Krystina L. Ho | Attorney | Counsel for AbbVie, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Michelle Streifthau-Livizos | Attorney | Counsel for AbbVie, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Scott F. Peachman | Attorney | Counsel for AbbVie, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Morris James LLP | Law Firm | Representing AbbVie, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Saul Ewing Arnstein & Lehr LLP | Law Firm | Representing AbbVie, Inc.Search in Eureka ↗ |
| Defendant counsel | Amlan Ray | Attorney | Counsel for Dr. Reddy’s Laboratories, Ltd.Search in Eureka ↗ |
| Defendant counsel | Anandita Vyakarnam | Attorney | Counsel for Dr. Reddy’s Laboratories, Ltd.Search in Eureka ↗ |
| Defendant counsel | Autumn N. Nero | Attorney | Counsel for Dr. Reddy’s Laboratories, Ltd.Search in Eureka ↗ |
| Defendant counsel | Beth C. Finkelstein | Attorney | Counsel for Dr. Reddy’s Laboratories, Ltd.Search in Eureka ↗ |
| Defendant counsel | Brandon M. White | Attorney | Counsel for Dr. Reddy’s Laboratories, Ltd.Search in Eureka ↗ |
| Defendant counsel | Christopher D. Jones | Attorney | Counsel for Dr. Reddy’s Laboratories, Ltd.Search in Eureka ↗ |
| Defendant counsel | Constance S. Huttner | Attorney | Counsel for Dr. Reddy’s Laboratories, Ltd.Search in Eureka ↗ |
| Defendant counsel | Daniel Taylor | Attorney | Counsel for Dr. Reddy’s Laboratories, Ltd.Search in Eureka ↗ |
| Defendant counsel | Eve H. Ormerod | Attorney | Counsel for Dr. Reddy’s Laboratories, Ltd.Search in Eureka ↗ |
| Defendant counsel | Jonathan I Tietz | Attorney | Counsel for Dr. Reddy’s Laboratories, Ltd.Search in Eureka ↗ |
| Defendant counsel | Neal C. Belgam | Attorney | Counsel for Dr. Reddy’s Laboratories, Ltd.Search in Eureka ↗ |
| Defendant law firm | Smith, Katzenstein & Jenkins LLP | Law Firm | Representing Dr. Reddy’s Laboratories, Ltd.Search in Eureka ↗ |
| Presiding judge | Judge Mitchell S. Goldberg | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The stipulated consent order is unusually explicit in its acknowledgement of infringement: the court formally adjudged ANDA 214733 as a technical act of infringement under § 271(e)(2)(A) for all four patents. This is not a no-contest dismissal — it is a court decree carrying full injunctive force. The without-prejudice dismissal of all other claims is a standard Hatch-Waxman settlement mechanism that resolves the current action without binding the parties on validity or other disputes in any future proceeding involving different products.
US10993942B2, US11110087B2 & US11369599B2 — Venetoclax (VENCLEXTA®) Patent Portfolio
The three identified patents — US10993942B2 (application US16/827650), US11110087B2 (application US17/187468), and US11369599B2 (application US14/340435) — form part of a broader portfolio covering venetoclax, the active ingredient in VENCLEXTA®. Venetoclax is a selective BCL-2 inhibitor approved for the treatment of chronic lymphocytic leukaemia (CLL), small lymphocytic lymphoma (SLL), and acute myeloid leukaemia (AML) in combination regimens. The asserted patents cover aspects of the compound’s composition, pharmaceutical formulation, and/or methods of use, with application filings spanning multiple years — a hallmark of evergreening strategy in oncology drug development.
The commercial stakes are substantial: VENCLEXTA® has achieved multi-billion dollar annual revenues globally, making it a prime target for Paragraph IV ANDA filings by generic manufacturers. Holding four separate patents across formulation and composition aspects creates substantial litigation leverage, as any ANDA filer must successfully invalidate or design around all asserted patents to achieve market entry. The consent order in this case demonstrates that the portfolio’s enforceability has so far withstood challenge at the district court level, raising the risk profile for other potential generic entrants.
Should you run an FTO analysis against the VENCLEXTA® patent portfolio?
Any company developing or formulating venetoclax-containing products — including alternative dosage forms, combination therapies, or next-generation BCL-2 inhibitors — should treat this case as a prompt for a structured freedom-to-operate analysis. The four patents asserted here cover different aspects of the venetoclax product, and the consent order confirms their enforceability has not been successfully challenged by a well-resourced generic entrant. Biosimilar and generic developers, as well as companies building on BCL-2 pathway biology, face real clearance risk.
PatSnap Eureka’s FTO Search Agent can map the full venetoclax patent landscape — including continuation families, patent-term extension filings, and post-grant challenge history — against your specific compound or formulation. Eureka surfaces claim-level analysis across the AbbVie and Genentech portfolio, flags active exclusivities, and helps IP teams identify design-around opportunities or validity risks before committing to costly ANDA or development programmes.
Run a freedom-to-operate analysis on US11369599B2 to assess your product’s exposure
Run FTO in Eureka →Similar Hatch-Waxman oncology patent cases in Delaware District Court
These Delaware District Court Hatch-Waxman cases involve comparable ANDA infringement disputes over oncology small-molecule patent portfolios — relevant for benchmarking venetoclax litigation strategy.
What this case signals for the Hatch-Waxman oncology drug IP landscape
The VENCLEXTA® consent order reinforces how layered patent portfolios and Hatch-Waxman strategy interact to extend branded exclusivity in high-value oncology indications.
Multi-patent portfolios compel consent outcomes in Hatch-Waxman litigation
Defending against four patents simultaneously — covering different aspects of a drug’s composition, formulation, and use — significantly raises litigation costs and risk for ANDA filers. The Dr. Reddy’s consent order is consistent with a pattern where the breadth of the innovator’s portfolio makes a consent injunction a commercially rational outcome for the generic challenger rather than proceeding to trial.
Without-prejudice carve-outs preserve future legal options for both sides
The stipulation’s explicit preservation of future claims regarding non-ANDA 214733 products is a deliberate negotiation outcome. For AbbVie and Genentech, it preserves enforcement rights. For Dr. Reddy’s, it signals that alternative product formulations or new ANDAs may remain viable strategic avenues. IP teams tracking the venetoclax space should monitor new ANDA filings or IPR petitions from Dr. Reddy’s.
AbbVie v Dr. — key questions answered
The case was resolved on 17 December 2024 by a stipulated consent order. The court adjudged that Dr. Reddy’s ANDA 214733 constituted a technical act of infringement of four venetoclax patents under 35 U.S.C. § 271(e)(2)(A). Dr. Reddy’s was permanently enjoined from commercialising generic venetoclax tablets (10 mg, 50 mg, 100 mg) for the life of all four patents. All remaining claims were dismissed without prejudice and both parties waived their right to appeal.
Four patents were asserted: US10993942B2, US11110087B2, US11369599B2, and a fourth patent referenced in the consent order as the ‘128 Patent. All four were found to have been technically infringed by the filing of ANDA 214733 under 35 U.S.C. § 271(e)(2)(A). The injunction covers the full term of each patent including any patent-term extensions and paediatric exclusivities.
In this context, dismissal without prejudice applies only to the claims, counterclaims, and defences not resolved by the consent order itself. It means those residual claims were not adjudicated on their merits and could theoretically be re-raised in a future action. Critically, the consent order’s injunction and infringement finding are fully enforceable and were not dismissed — only the peripheral allegations were cleared from the docket without a binding merits ruling.
The consent order explicitly preserves the right of Dr. Reddy’s to assert claims or defences in any future action regarding the four asserted patents and a product other than the specific generic venetoclax tablets described in ANDA 214733. Dr. Reddy’s also retains access to USPTO post-grant proceedings (such as IPR petitions) as a separate challenge route, as the without-prejudice dismissal does not extinguish validity challenges outside this district court action.
While the precise reasons are not disclosed in the public record, a 1,610-day duration in a multi-patent Hatch-Waxman case is consistent with the complexity of litigating four separate patents covering different aspects of a blockbuster oncology drug. Extended timelines in such cases typically reflect claim construction proceedings, extensive expert discovery, and prolonged settlement negotiations. The consent order’s carve-outs suggest the parties ultimately negotiated a structured resolution rather than proceeding to a merits trial.
PatSnap Eureka searches patents and litigation data to answer instantly.